Serum Nitric Oxide as a Biochemical Marker for Diabetic Nephropathy

Eman Y. Mohammed, Dhia J. Al-Timimi, Suad Y. Al-Kass, Ahmed H. Mehdi, Ali I. Mohammed

Abstract


The realization that diabetic nephropathy is associated with nitric oxide production, create a great incentive to study the level of nitric oxide in diabetic patients and to ascertain its relation with renal impairment. This study aimed to find out whether serum nitric oxide can be considered as a biochemical marker in diabetic nephropathy. A total of 240 subjects (age and sex matched) were enrolled in this study and divided into two groups; diabetic group included 120 diabetic patients (type 1 and type 2) and control group included 120 apparently healthy subjects. Blood samples were collected from all the individuals and laboratory measurements for HbA1c, serum glucose, urea, creatinine and nitric oxide were done. Urine samples were also collected for measurement of microalbuminuria. The patients were classified into three main groups on the basis of blood pressure and nephropathy. Group 1: Diabetic, normotensive patients; Group 2: Diabetic, hypertensive patients; Group 3: Diabetic, hypertensive patients with nephropathy then group 3 was divided into 3 subgroups according to the stage of diabetic nephropathy: Diabetic incipient nephropathy, diabetic overt nephropathy and diabetic with end stage renal disease. The mean value of serum nitric oxide level was significantly lower in diabetic patients when compared to controls (26.1±1.37 µmol/l) for diabetic normotensive patients, (15.2±0.97 µmol/l) for diabetic hypertensive patients, and (17.4±17.5 µmol/l for diabetic hypertensive patients with nephropathy versus 30.6±2.18 µmol/l for healthy controls). The mean serum nitric oxide (50.9±1.89 µmol/l) and glomerular filtration rate (132±13.9 ml/min), were significantly higher in diabetic patients with early nephropathy (Diabetic incipient nephropathy) than diabetic overt nephropathy (10.1±1.32µmol/l and 44.5±6.36 ml/min), and diabetic with end stage renal disease ((4.9±0.63 µmol/l and 10.5±3.16 ml/min). It is evident from the present study that serum nitric oxide is the major biochemical marker for microvascular complications of diabetes mellitus such as nephropathy. The data support the use of raised serum nitric oxide as a marker for early incipient diabetic nephropathy and a low serum nitric oxide for overt and end stage diabetic nephropathy. The decreases being proportionate to the degree of renal impairment.

Full Text:

PDF

References


Albert, K. and Zimmet, P. (2004). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabetic Medicine., 15:539-553.

American Diabetic Association (2011). Diagnosis and Classification of Diabetes Mellitus. Diabetic Care., 35:(1), 64-71.

Azakimori,Y.; Yorioka, N.; Yamamato, I.; Okumoto, S.; Doi, S. and Hirai, T. (2001). Endothelial nitric oxide synthase intron 4 polymorphism influences the progression of renal disease. Nephron., 17:(10), 2664-2669.

Baylis, C. (2008). Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol., 249:1-9.

Bonetti, P.; Lerman, L. and Lerman, A. (2003). Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol., 23:168-175.

Buchholz, A. and Bugaresti, J. (2005). A review of body mass index and waist circumference as markers of obesity and coronary heart disease risk in persons with chronic spinal cord injury. Spinal Cord., 43:513-518.

Ethel, M.; Ann, F.; Steven, H. and Sadowsky, M. (2011). Blood Pressure Measurement Guidelines for physical therapists. Cardiopulmonary Physical Therapy Journal., 2: 22.

Gault, M.; Longerich, L.; Harnett, J. and Wesolowsky, C. (1992). Predcting glomerular function from adjusted serum creatinine. Nephron., 16:(1), 31-41.

Jorge, L.; Mirela, J.; Sandra, P.; Luis, H.; Maria, L. and Themis, Z. (2005). Diabetic Nephropathy: Diagnosis, Prevention and Treatment. Diabetes Care., 28:176-188.

Knowles, BJ.; Haigh, WB.; Michaud, GC. and Marchesi, VT. (1986). A monoclonal antibody-based immunoassay for hemoglobin A1C. Diabetes., 35:94.

Lockhart, J.; Larson, S. and Knox, G. (1994). Perfusion pressure and volume status determine the microvascular response of the rat kidney to N-monomethyl-L-arginine. Circ Res., 75:829-835.

Moncada, S. and Higgs, A. (1993). The L-arginine-nitric oxide pathway. New Engl J Med., 329:2002-2012.

Nakagawa, T. (2007). Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol., 292:1665-1672.

Oh, S.; Moon, J. and Park, S. (2005). Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing. Clin Chim Acta., 356:172-177.

Palmer, R. and Ashton, D. (1988). Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature., 333:664-666.

Prabhakar, S. (2004). Role of nitric oxide in diabetic nephropathy. Rev Semin

Nephrol., 24:(4), 333-344.

Sastry, K.; Mougdgal, R.; Mohan, J.; Tyagi, J. and Rao, G. (2002). Spectrophotometric Determination of Serum Nitrite and Nitrate by Copper-Cadmium Alloy. Analytical Biochemistry., 306:79-82.

Segal, M.; Baylis, S. and Johnosn, R. (2006). Endothelial Health and Diversity in the Kidney. J Am Sol Nephrol., 17:323-324.

Sugimoto, H.; Shikata, K.; Wada, J.; Horiuchi, S. and Makino, H. (1999). Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguainidine ameliorates the overexpression of tumor necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia., 42:878-886.

Tarnow, L.; Hovind, P.; Teerlink, T.; Coen, D. and Parving, H. (2004). Elevated Plasma Asymmetric Dimethylarginine as a Marker of Cardiovascular Morbidity in Diabetic Nephropathy in Type 1 Diabetes. Diabetic Care., 27: 765-769.

Yan, S.; Schmidt, A.; Anderson, G.; Zhang, J.; Brett, J. and Zou, Y. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors / binding proteins. J Biol Chem., 296:9889-9897.

Zats, R. and Nussi, G. (1991). Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am J Physiol., 30:360-363.

Zelmanovitz, T.; Gerchman, F.; Balthazar, A.; Thomazelli, F.; Jorge, D. and Canani, H. (2009). Diabetic Nephropathy. Bio Med Central., 1:10.


Refbacks

  • There are currently no refbacks.